EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pheochromocytomas and Paragangliomas—Current Management

Adam Brewczyński, Agnieszka Kolasińska-Ćwikła, Beata Jabłońska iD, Lucjan Wyrwicz

Cancers · 19.03.2025 · 17 (6) · 1029

DOI: 10.3390/cancers17061029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.03.2025. Verfasst von Adam Brewczyński und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology and Radiotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pheochromocytomas and paragangliomas (PPGLs) are infrequent neuroendocrine hypervascular neoplasms arising within different sites of the paraganglion system. They are divided into sympathetic (including pheochromocytomas and extraadrenal paragangliomas) and parasympathetic extraadrenal tumors. These tumors are usually not malignant and grow slowly; about 90% of them are found in the adrenal paraganglia (pheochromocytomas). Extraadrenal tumors are most frequently located in the abdominal cavity (85%), followed by the thoracic cavity (12%), and head and neck (3%). About 25% of PPGLs are related to germline mutations, which are risk factors for multifocal and metastatic disease. In PPGL diagnostics, laboratory, biochemical, and imaging (anatomical and functional) examinations are used. Surgery is the standard management choice for locoregional disease. For patients who are not candidates for surgery and who have stable, not-growing, or slow-growing tumors, active observation or other less invasive techniques (i.e., stereotactic surgery, hypofractionated stereotactic radiotherapy) are considered. In metastatic disease, systemic therapies (tyrosine kinase inhibitors [TKIs], mTORC1 inhibitor everolimus, immunotherapy, cold somatostatin analogs [biotherapy], and radioligand therapy) are used. The prognosis for PPGLs is quite good, and the 5-year survival rate is >90%. The goal of this paper is to review knowledge on the etiopathogenesis, current diagnostics, and therapy for PPGL patients. Our paper is particularly focused on the current management of PPGLs.

Schlagwörter

Stichwörter der Autor:innen

SDHx mutationadrenalectomycarotid body tumorjugulo-tympanic paragangliomaparagangliomapheochromocytomastereotactic radiosurgeryvagal paraganglioma

Autor:innen und Institutionen

  • Oncology and Radiotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland.
  • Department of Digestive Tract Surgery, Medical University of Silesia, 40-752 Katowice, Poland.

ORCID-Profile: Beata Jabłońska

Zitieren

APA

Brewczyński, A., Kolasińska-Ćwikła, A., Jabłońska, B., & Wyrwicz, L. (2025). Pheochromocytomas and Paragangliomas—Current Management. Cancers, 17(6), 1029. https://doi.org/10.3390/cancers17061029

Vancouver

Brewczyński A, Kolasińska-Ćwikła A, Jabłońska B, Wyrwicz L. Pheochromocytomas and Paragangliomas—Current Management. Cancers. 2025;17(6):1029. doi:10.3390/cancers17061029

BibTeX
@article{Brewczyski2025,
  author = {Brewczyński, Adam and Kolasińska-Ćwikła, Agnieszka and Jabłońska, Beata and Wyrwicz, Lucjan},
  title = {Pheochromocytomas and Paragangliomas—Current Management},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {6},
  pages = {1029},
  doi = {10.3390/cancers17061029}
}
Kostenlos starten →